HOME >> MEDICINE >> NEWS
Imatinib (Gleevec) has activity in AIDS-related Kaposi's sarcoma

Alexandria, VA--A new clinical study has shown that imatinib mesylate (Gleevec) has activity in AIDS-related Kaposi's sarcoma (KS). Imatinib inhibits important pathways that spur cancer growth, resulting in the regression of KS tumors within 4 weeks in some patients. The study will be published November 30 in the Journal of Clinical Oncology (JCO).

"Imatinib is a targeted therapy originally shown to be effective in treating chronic myelogenous leukemia and gastrointestinal stromal tumors. This study and others are showing that the drug is also active in other cancers that express some of the same proteins," said Henry B. Koon, MD, Instructor of Medicine, Beth Israel Deaconess Medical Center/Harvard Medical School in Boston, and lead author of the study. "Studies like this one represent an exciting time in oncology, when our understanding of the development of diseases like KS coincide with the availability of effective treatments. Further research on imatinib in KS patients will be needed to determine appropriate dosing schedules."

Kaposi's sarcoma is an AIDS-defining illness characterized by soft purplish lesions on the skin, mucous membranes, and internal organs. Although the incidence of KS has declined dramatically in the developed world since the advent of highly active antiretroviral therapies (HAART), it remains a significant cause of morbidity and mortality for AIDS patients in the United States and a major cause of mortality in the third world, given the limited number of effective treatments for KS.

Researchers examined the response of Kaposi's sarcoma to imatinib, a drug known to inhibit the PDGF-R and/or c-kit pathways that are responsible for the growth of other cancers, such as chronic myelogenous leukemia, gastrointestinal stromal tumors (GIST), and bone sarcomas of the head and neck. Given that PDGF-R and c-kit also play a role in the development of KS, researchers theorized that imatinib may be an effective strategy
'"/>

Contact: Danielle Potuto
potutod@asco.org
703-519-1422
American Society of Clinical Oncology
30-Nov-2004


Page: 1 2

Related medicine news :

1. Imatinib shows early promise against Ewings sarcoma
2. Brain activity prior to treatment flags vulnerability to antidepressant side effects
3. Physical activity linked to protection from Parkinsons disease
4. Brain activity of men and women during hostile or impulsive acts differs less on nicotine
5. Abnormal brain activity during the observation of others actions
6. Increased physical activity not linked to ALS risk
7. Maintaining physical activity linked to less cognitive decline in older men
8. Daily social/physical activity improves sleep and cognition in the elderly
9. Celecoxib shows surprising activity against estrogen receptors
10. Jefferson scientists find way to see breast cancer activity from outside the body
11. Brain activity reflects complexity of responses to other-race faces

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Imatinib Gleevec has activity AIDS related Kaposi sarcoma

(Date:10/31/2014)... effort by the National Institutes of Health will ... to reframe mental health research, from diagnosis to ... recently established by the National Institute of Mental ... development of the institute,s RDoC initiative. , ... accelerate the pace of research that translates basic ...
(Date:10/31/2014)... News) -- A comparison of two of the most ... gastric bypass helped patients shed more excess pounds than ... short-term complications and long-term hospitalizations. Gastric-bypass surgery makes ... your body does not absorb all the calories from ... Health. Gastric banding is a type of weight-loss procedure ...
(Date:10/31/2014)... Steven Reinberg HealthDay Reporter THURSDAY, ... increase slightly the risk of broken bones and injured joints, a ... found that among 7 percent of people who had an eczema ... joint injury and 0.6 percent had an injury that caused a ... with the skin condition had more than double the risk of ...
(Date:10/30/2014)... one day provide new treatments for injuries and damage ... , Cartilage, for example, is a hard material that ... work smoothly. UC Davis biomedical engineers, exploring ways to ... outside the body, report new developments this week in ... Sciences . , "The problem with engineered tissue is ...
(Date:10/30/2014)... , A mathematical model developed by NIH grantees predicts ... to prevent HIV infection via vaginal sex, whereas just ... infection via anal sex. This finding helps explain why ... PrEP, in women failed to show efficacy. Participants in ... of Truvada and tenofovir (another antiretroviral) for HIV prevention ...
Breaking Medicine News(10 mins):Health News:NIMH creates new unit to support its research domain criteria initiative 2Health News:Study Compares 2 Common Weight-Loss Surgeries 2Health News:Study Compares 2 Common Weight-Loss Surgeries 3Health News:Eczema Tied to Bone Fracture Risk in Study 2Health News:Making lab-grown tissues stronger 2Health News:Model by NIH grantees explains why HIV prevention dosing differs by sex 2
(Date:10/31/2014)... LONDON , October 31, 2014 ... (NYSE: MDT ), Abbott Laboratories (NYSE: ... Inc. (NYSE: RMD ), and Covidien PLC (NYSE: ... at: http://investor-edge.com/register . The US markets on ... the Dow Jones Industrial Average finished at 17,195.42, up 1.30% ...
(Date:10/31/2014)... Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, ... 30, 2014. Brian M. Culley, the ... productive for Mast. Consistent with prior guidance, our 388-patient pivotal ... is on track to complete enrollment by the end ... in the U.S. and more than ten study sites ...
(Date:10/31/2014)... , October 31, 2014 ... a clinical-stage pharmaceutical company focused on the development ... company will host a conference call to discuss ... trial of ORMD-0801, the company,s proprietary oral insulin ... November 3, 2014 at 10:00 a.m. Eastern time. ...
Breaking Medicine Technology:Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 2Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 3Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 4Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 2Mast Therapeutics Reports Third Quarter 2014 Financial Results 3Mast Therapeutics Reports Third Quarter 2014 Financial Results 4Mast Therapeutics Reports Third Quarter 2014 Financial Results 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 6Mast Therapeutics Reports Third Quarter 2014 Financial Results 7Mast Therapeutics Reports Third Quarter 2014 Financial Results 8Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3
Cached News: